Introduction
More than 130 million people are chronically infected with HCV. End stage liver disease associated with chronic HCV infection is a leading indication for liver transplantation 1 . However, reinfection is universal and more than 25 % of patients develop recurrent hepatitis in the donor organ.
HCV infects hepatocytes and establishes a chronic infection in the majority of cases. Viral isolates are grouped into six genotypes and more than 100 subtypes 2 . Chronic HCV infection is treated with pegylated Interferon alpha (PEG-IFN-α) and ribavirin curing 80% of genotype 2 and 3 and approximately 50% of genotype 1-infected individuals 1 . PEG-IFNα and ribavirin have also been applied in patients after liver transplantation. However, in this context, efficacy is lower with sustained virological responses ranging from 20% to 45% only 3 .
Notably, the outcome of hepatitis C after liver transplantation has worsened during the last 10-15 years 4 . Several factors have been suspected to be accountable including an increased donor age 5 . Generally, HCV RNA levels are higher after transplantation than before and high virus titers are associated with a worse long term outcome 6 , 7 . The immunosuppressive treatment has been supposed to alter the course of hepatitis C in liver transplant recipients. While cyclosporin A (CsA) and mycophenolate mofetil (MMF) have antiviral effects in tissue culture and m-TOR antagonists have antifibrotic properties in vivo [8] [9] [10] , use of corticosteroids has been a matter of debate. Repeated usage of high doses of corticosteroids have been associated with more rapid fibrosis progression and poor longterm outcome of graft hepatitis C [11] [12] . Nevertheless, steroid boli therapies are still applied after liver transplantation for hepatitis C, and the molecular mechanisms responsible for the steroid-treatment associated exacerbation of HCV infection are currently unclear.
Recently, a cell culture system permissive for HCV replication and reproducing the complete replication cycle was developed 13 . This HCV infection model is based on the JFH1 strain (genotype 2a), which replicates efficiently in Huh-7 cells. These advances allowed us to
Material and Methods

Drugs:
Cyclosporin A, everolimus, basiliximab, and enteric-coated mycophenolate sodium were provided by Novartis, Basel, Switzerland. Tacrolimus, azathioprine, dexamethasone, prednisolone, fludrocortisone, cholesterol, and RU-486 were purchased from Sigma-Aldrich, Seelze, Germany or from Sanofi Aventis, Frankfurt, Germany.
Plasmids:
The reporter virus genome Luc-Jc1 and expression plasmids for HCV E1/E2 proteins of the J6CF (genotype 2a) or the Con1 isolate (genotype 1b), have been described recently [14] [15] 16 .
The murine leukemia virus (MLV) based retroviral vector pRV-F-Luc-IZ is a derivative of pczCFG5-IZ 17 . Briefly, this vector carries a chimeric 5´LTR in which the MLV-U3 region was replaced by a cytomegalovirus immediate early promoter. The transgene (firefly luciferase) is inserted into the env locus of the original MLV genome and is followed by the internal ribosome entry site of the encephalomyocarditis virus (EMCV) and the ble resistance gene conferring resistance to Zeozin TM (Invitrogen, Karlsruhe, Germany).
Cell Culture:
Low passage Huh-7.5 cells were cultured in Dulbecco`s modified Eagle medium (DMEM, Invitrogen) with 10% fetal bovine serum (FCS Gold, PPA, Coelbe, Germany) , 1x nonessential amino acids (Invitrogen), 100µg/ml streptomycin (Invitrogen) and 100 IU/ml penicillin (Invitrogen).
HCV luciferase replication and infection assays
Huh-7.5 cells were transfected and infected as described recently 14 . Drugs were applied as indicated in the text.
Preparation of retroviral pseudo-particles
MLV-based pseudotypes were generated by transfection of 293T cells. Briefly, 1. .
Quantitative detection of HCV RNA and core protein.
HCV core protein was measured using an HCV core antigen kit (Wako Chemicals, Neuss, Germany). RNA was isolated from infected cells using a Nucleo Spin RNAII Kit (MachereyNagel, Düren, Germany). HCV RNA was quantified using a Light Cycler 480 (Roche, Mannheim, Germany) as described recently 19 . 
Flow cytometry
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Western blot analysis
Cells were washed once with PBS and lysed in sample buffer (400 mM Tris, pH 8. Göttingen, Germany) and normalized for the actin-specific signal.
Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR)
The mRNA levels of SR-BI, occludin and GAPDH were quantified using the LightCycler 480 system (Roche Diagnostics, Mannheim, Germany), the QuantiTect Primer Assay kit (Qiagen) and gene-specific primers.
Indirect immunofluorescence
Huh-7.5 cells were seeded onto glass coverslips in 24-well plates at a density of 2× 10 4 cells/cm 2 per well and were fixed 48 h post infection using PBS supplemented with 3% paraformaldehyde for 10 min at room temperature. Staining of NS5A was performed as described 19 using the 9E10 hybridoma supernatant at a dilution of 1:2,000.
Immunohistochemical staining and virus titration
Virus titers were measured using the limiting dilution assay as described recently 19 . Virus titers (50% tissue culture infective dose [TCID 50 /ml]) were calculated based on the method of Spearman and Kärber [22] [23] .
Human Primary Hepatocyte Cultures
We obtained liver tissue from donors undergoing hemihepatectomy or atypic liver resection without primary liver disease (e.g. colorectal metastases or metastases of a mamma carcinoma or melanoma). These donors were negative for Hepatitis A, B and C and HIV and gave their written consent for this study.
Hepatocytes were isolated from an encapsulated liver sample by a two-step perfusion technique 24 . Cells were inoculated with HCVcc or patient sera (genotype 1; viral load > 5x10 6 IU/ml; HAV, HBV, HIV negative) for 3h. HCV replication was measured by qRT-PCR up to two weeks after infection.
The study was approved by ethics committee of the Hannover Medical School. Patients provided written informed consent.
Results
Glucocorticosteroids (GCs) slightly reduce HCV RNA replication but increase infectivity
We evaluated the effects of common immunosuppressive drugs on HCV replication and infectivity, using firefly luciferase reporter viruses based on the intragenotypic genotype 2a chimera Jc1 (Luc-Jc1; Fig. 1A 
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)
. These results are summarized in Table I . In agreement with previous data
HCV entry is enhanced by GCs
To characterize the stimulation of virus entry by GCs, we administered prednisolone at different intervals during the early phase of infection. As shown in Figure 2A , application of prednisolone shortly before, during, or directly after inoculation increased HCV infectivity, while thereafter infection was not changed. Notably, addition of the drug shortly prior to the virus stimulated infection, suggesting that GCs transiently act on the cell surface rather than the virion.
To specifically assess the influence on HCV entry, we utilized HCV pseudoparticles (HCVpp). Since these are retroviral cores carrying HCV glycoproteins in their envelope [28] [29] ,
only the early steps of virus entry are HCV dependent, i.e. virus binding, uptake and virusmembrane fusion, whereas all later steps are dependent on retroviral proteins. Using this approach we observed that stimulation by prednisolone is HCV specific, since retroviral pseudotypes with the glycoprotein of the vesicular stomatitis virus (VSV-G) were not affected ( Fig 2B) . As infectivity of HCVpp with J6CF (genotype 2a) or Con1 (genotype 1b)
glycoproteins was stimulated, the enhancement of HCV infection by prednisolone is not genotype-or isolate-specific (Fig. 2B ).
To analyze the mechanism by which GCs facilitate infection, we investigated the kinetic of HCV uptake into Huh-7.5 cells. To this end, we employed two potent inhibitors of HCV entry, namely CD81-specific antibodies which block interaction of HCV with this crucial entry factor, and concanamycin A, an inhibitor of endosomal acidification, which prevents the low pHdependent viral fusion mechanism. These agents were either added together with the virus ( Interestingly, HCV was resistant to CD81-specific antibodies and inhibitors of low pH-induced fusion (Con A) more rapidly in the presence of prednisolone compared to the solvent control ( Fig. 2C ). Control antibodies (CD13) had no effect irrespective of prednisolone and time point of application. These results imply that GCs accelerate both uptake of HCV into host cells (acquisition of resistance to CD81 antibodies) and escape from endosomes (concanamycin A resistance) indicating that GCs facilitate infection by enhancing the kinetic of (an) early step(s) of HCV entry.
The GC prednisolone upregulates SR-BI cell surface expression and occludin expression
Due to these results we hypothesized that GCs modulate the abundance of host factors crucial for virus entry, and investigated expression of proteins implicated in HCV infection.
We analyzed expression of all four key entry factors of HCV, i.e. CD81 , and occludin 33 . Since HCV is associated with lipoproteins of low and very low density [34] [35] , natural ligands of the LDL receptor, and since LDL-R was reported to function during HCV entry 36 , we also determined LDL-R expression. As shown in Figure 3A , claudin-1 and LDLreceptor expression were not affected by prednisolone. However, occludin was upregulated by prednisolone to levels ca. 18-fold higher compared to untreated cells (Fig. 3A) .
While CD81 surface expression was not altered, the abundance of SR-BI at the cell surface increased 3-fold ( Figure 3B ). These results indicate that GCs upregulate expression of two key host factors necessary for productive HCV infection. Interestingly, the upregulation was rapid and transient ( Supplementary Fig. 1 ) which is in agreement with the kinetics of the stimulatory effect of GCs on HCV cell entry.
RU-486, an antagonist of GC signalling, counteracts upregulation of SR-BI and occludin mRNA and protein level and also enhancement of HCV entry
To analyze how prednisolone upregulates SR-BI and occludin expression, we quantified mRNA levels of both proteins in prednisolone-treated Huh-7.5 cells using qRT-PCR. These analyses revealed that prednisolone treatment for 5 h increased the abundance of both mRNAs in a dose-dependent manner, while copy numbers of GAPDH were unaffected (Fig.   4A ). To establish a direct link between GC signalling, upregulation of mRNA and protein levels of SR-BI and occludin, and enhancement of HCV entry, we utilized RU-486, a drug that antagonizes GC signalling by direct binding to the GC receptor 37 . Remarkably, 10 µg/ml RU-486 fully abolished stimulation of HCV cell entry by prednisolone (Fig. 4B ) and at the same time interfered with prednisolone-dependent accumulation of SR-BI and occludin mRNA and protein levels (Fig 4C and D) . Notably, RU-486 treatment alone had no effect on HCV infectivity and replication ( Supplementary Fig. 2 ). Direct knock down of SR-BI and occludin mRNA by siRNA interference showed inhibitory effects, but the results were inconclusive due to inhibitory effects also seen for control scrambled RNA (data not shown)..
Together, these results agree with previous findings implicating GCs with upregulation of SR-BI and occludin [38] [39] [40] and provide strong evidence that prednisolone enhances HCV entry via GC signalling-dependent upregulation of these HCV entry factors.
Enhancement HCV infection and dissemination by GCs is cell density-dependent
Since claudin is a component of tight junctions and as these structures likely form in a cell density-dependent manner, we assessed the influence of cell density on the degree of infection enhancement by prednisolone. To this end, Huh-7.5 cells were seeded in different cell densities and infected with Luc-Jc1 in the presence or absence of prednisolone.
Remarkably, the stimulatory effect of prednisolone was completely lost at low cell density, 100-fold and almost 1,000-fold higher HCV RNA copy numbers compared to CsA treated controls, respectively ( Fig. 6B and C) . When adding 100 µg/ml prednisolone, Jc1 RNA levels were slightly elevated throughout the time course. Importantly, HCV RNA copy numbers in case of the patient serum were about 5-fold higher when prednisolone was present. In line with our data described above, increased HCV propagation in PHHs was also accompanied by upregulation of SR-BI and occludin mRNAs ( Supplementary Fig. 3 ).These data indicate that GCs not only enhance infection of hepatoma cell lines by cell culture-derived HCV particles but also facilitate propagation of these viruses as well as of natural HCV from patients in primary human hepatocytes.
Discussion
In this study we observed that GCs slightly reduce HCV RNA replication, while strongly enhancing HCV infectivity. This stimulatory effect was associated with an upregulation of expression of two essential HCV entry factors (occludin and SR-BI) via signalling through the GC receptor. These results highlight a novel mechanism how GCs may also increase HCV infection in vivo.
Studying the effects of corticosteroids on HCV Con1 subgenomic replicon cells, Henry et al noted slightly reduced HCV RNA replication 25 . These authors therefore assumed that adverse effects of corticosteroids on HCV-infection were due to dampening of immune responses and thus indirect. While this is likely one mechanism that facilitates HCV replication in vivo, our findings suggest that GCs directly increase HCV dissemination through enhancement of HCV entry. The steroid-induced relative increase in HCV infectivity was more pronounced than the reduction in HCV replication. Importantly, this was not only true in reporter assays that test either entry or RNA replication. Also when using reporter viruses and an assay for the complete replication cycle, we noted a significant increase in virus propagation due to GCs. Moreover, HCV spread more rapidly in naive and in DMSO treated differentiated Huh-7.5 cells in the presence of prednisolone. Together these data indicated that the enhancement of virus entry was dominant over the minor inhibition of RNA replication.
Analyzing the mechanism permitting increased infection and more rapid virus spread, we made two important observations: First, we noted faster virus uptake and escape from endosomes in the presence of prednisolone. As a consequence, susceptibility of HCV infection to blockade by CD81-specific antibodies or concanamycin A, was lost more quickly.
In vivo accelerated virus entry may contribute to immune evasion via escape from virusneutralizing antibodies. While this kinetic effect may partially explain a more rapid spread in tissue culture, we believe that the latter is primarily due to an overall enhancement of virus infection. This direct stimulation of HCV infection may be most directly evident in our experiments with retroviral pseudotypes. Since these particles consist of retroviral cores enveloped by HCV glycoproteins E1, E2, they specifically permit assessment of utilization of host cell entry factors by HCV. Importantly, while pseudotypes with E1-E2 complexes from two different isolates were stimulated, those particles carrying VSV-G were not. These data imply that steroid-dependent facilitation of uptake and infection does not universally apply to enveloped viruses, may be general for HCV, but at least does not only affect a single HCV isolate.
Our second finding relates to the mode by which GCs specifically enhance HCV infection:
Our results indicate that this is due to upregulation of SR-BI and/or occludin, two host factors crucial for HCV infection. The increase of mRNA and protein levels and also enhancement of HCV infection were ablated by pre-treatment with RU-486, an antagonist of GC signalling.
Moreover, fludrocortisone and cholesterol did not stimulate HCV infection. Therefore, we can rule out that interactions of GCs or more generally of compounds that share a steroid scaffold are sufficient to increase HCV infection in a rather non-specific manner. Rather, we conclude that GCs increase abundance of SR-BI and occludin via signalling through the GC receptor thus stimulating HCV cell entry.
It is puzzling that at low cell density GCs did not enhance HCV infection. However, it is possible that under these conditions neither entry factor limits HCV infection. In fact, the cell 
